Загрузка...
Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil
A dry-powder inhaled formulation of treprostinil (LIQ861) produced using PRINT® technology offers a substantial advantage over current nebulized therapy. Treprostinil is a synthetic prostacyclin analogue that is currently approved for inhalation administration to patients with pulmonary arterial hyp...
Сохранить в:
| Опубликовано в: : | Pulm Circ |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7682229/ https://ncbi.nlm.nih.gov/pubmed/33282202 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045894020971509 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|